215 related articles for article (PubMed ID: 34763232)
1. HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma.
Yu M; Yu S; Zhou W; Yi B; Liu Y
Int Immunopharmacol; 2021 Dec; 101(Pt A):108293. PubMed ID: 34763232
[TBL] [Abstract][Full Text] [Related]
2. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
3. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of CD163 as a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.
Li H; Wang D; Yi B; Cai H; Xi Z; Lou X; Li Z
Biomed Res Int; 2021; 2021():8357585. PubMed ID: 34395626
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of HOXC6 inhibits glioma cell proliferation and induces cell cycle arrest by targeting WIF-1 in vitro and vivo.
Yan TF; Wu MJ; Xiao B; Hu Q; Fan YH; Zhu XG
Pathol Res Pract; 2018 Nov; 214(11):1818-1824. PubMed ID: 30228024
[TBL] [Abstract][Full Text] [Related]
6. Identification of potential crucial genes and molecular mechanisms in glioblastoma multiforme by bioinformatics analysis.
Chen X; Pan Y; Yan M; Bao G; Sun X
Mol Med Rep; 2020 Aug; 22(2):859-869. PubMed ID: 32467990
[TBL] [Abstract][Full Text] [Related]
7. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
[TBL] [Abstract][Full Text] [Related]
8. Systematic identification of lncRNA-based prognostic biomarkers for glioblastoma.
Li M; Long S; Hu J; Wang Z; Geng C; Ou S
Aging (Albany NY); 2019 Nov; 11(21):9405-9423. PubMed ID: 31692451
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Differentially-Expressed Homeobox Family Genes on the Prognosis and HOXC6 on Immune Microenvironment Orchestration in Colorectal Cancer.
Qi L; Ye C; Zhang D; Bai R; Zheng S; Hu W; Yuan Y
Front Immunol; 2021; 12():781221. PubMed ID: 34950145
[TBL] [Abstract][Full Text] [Related]
10. ARL3 is downregulated and acts as a prognostic biomarker in glioma.
Wang Y; Zhao W; Liu X; Guan G; Zhuang M
J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870
[TBL] [Abstract][Full Text] [Related]
11. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
12. Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma.
Yu W; Ma Y; Hou W; Wang F; Cheng W; Qiu F; Wu P; Zhang G
Front Immunol; 2021; 12():706936. PubMed ID: 34899682
[TBL] [Abstract][Full Text] [Related]
13. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
14. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
15. Construction of co-expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma.
Zhou J; Guo H; Liu L; Hao S; Guo Z; Zhang F; Gao Y; Wang Z; Zhang W
J Cell Mol Med; 2021 Feb; 25(3):1633-1644. PubMed ID: 33449451
[TBL] [Abstract][Full Text] [Related]
16. Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma.
Liu B; Liu J; Liao Y; Jin C; Zhang Z; Zhao J; Liu K; Huang H; Cao H; Cheng Q
Med Sci Monit; 2019 May; 25():3624-3635. PubMed ID: 31094363
[TBL] [Abstract][Full Text] [Related]
17. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
18. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
19. Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma.
Haddad AF; Chen JS; Oh T; Pereira MP; Joshi RS; Aghi MK
Sci Rep; 2020 Oct; 10(1):17580. PubMed ID: 33067480
[TBL] [Abstract][Full Text] [Related]
20. Exploring the potential biomarkers for prognosis of glioblastoma via weighted gene co-expression network analysis.
Zhang M; Zhou Z; Liu Z; Liu F; Zhao C
PeerJ; 2022; 10():e12768. PubMed ID: 35111402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
